Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid.
作者信息
Zachariah U, Nair S C, Goel A, Balasubramanian K A, Mackie I, Elias E, Eapen C E
机构信息
Hepatology Department, Christian Medical College, Vellore, India.
Department of Transfusion Medicine and Immunohaematology, Christian Medical College, Vellore, India.
出版信息
Thromb Res. 2020 Aug;192:2. doi: 10.1016/j.thromres.2020.05.001. Epub 2020 May 5.
Abstract
摘要
相似文献
1
Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid.针对重症新型冠状病毒肺炎中血管性血友病因子水平升高和巨噬细胞激活：考虑小容量血浆置换和低剂量类固醇治疗。
Thromb Res. 2020 Aug;192:2. doi: 10.1016/j.thromres.2020.05.001. Epub 2020 May 5.
2
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients.新冠住院患者的ADAMTS13活性、血管性血友病因子、凝血因子VIII及D-二聚体
Thromb Res. 2020 Aug;192:174-175. doi: 10.1016/j.thromres.2020.05.032. Epub 2020 May 23.
3
Severe COVID-19 infection associated with endothelial activation.严重的2019冠状病毒病感染与内皮细胞激活有关。
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
4
COVID-19 and Hypercoagulability.新型冠状病毒肺炎与高凝状态
Clin Adv Hematol Oncol. 2020 Jul;18(7):386-389.
5
Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients.低ADAMTS 13血浆水平是COVID-19患者死亡率的预测指标。
Intern Emerg Med. 2020 Aug;15(5):861-863. doi: 10.1007/s11739-020-02394-0. Epub 2020 Jun 18.
6
Severe COVID-19 Is a Microvascular Disease.重症新型冠状病毒肺炎是一种微血管疾病。
Circulation. 2020 Oct 27;142(17):1609-1611. doi: 10.1161/CIRCULATIONAHA.120.050354. Epub 2020 Sep 2.
7
First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.首要的是不造成伤害——谨防重症新型冠状病毒肺炎患者进行治疗性血浆置换的风险。
Crit Care. 2020 Jun 18;24(1):363. doi: 10.1186/s13054-020-03070-7.
8
Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019.治疗性血浆置换-中和抗体联合疗法治疗重症2019冠状病毒病
J Infect Dis. 2020 Jul 6;222(3):509-510. doi: 10.1093/infdis/jiaa312.
9
Response to Malkovsky.对马尔科夫斯基的回应。
J Infect Dis. 2020 Jul 6;222(3):510-511. doi: 10.1093/infdis/jiaa313.
10
Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.先去除有害物质：采用恢复期血浆进行治疗性血浆置换治疗重症新型冠状病毒肺炎。
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12526-12527. doi: 10.1073/pnas.2006691117. Epub 2020 May 12.
引用本文的文献
1
Neurological sequelae of long COVID: a comprehensive review of diagnostic imaging, underlying mechanisms, and potential therapeutics.长期新冠的神经后遗症：诊断成像、潜在机制及潜在治疗方法的全面综述
Front Neurol. 2025 Feb 7;15:1465787. doi: 10.3389/fneur.2024.1465787. eCollection 2024.
2
Pathological Effects of SARS-CoV-2 Associated with Hematological Abnormalities.与血液学异常相关的新型冠状病毒2型（SARS-CoV-2）的病理效应
Curr Issues Mol Biol. 2023 Aug 28;45(9):7161-7182. doi: 10.3390/cimb45090453.
3
Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC).SARS-CoV-2 感染后后遗症（PASC）的发病机制。
Elife. 2023 Mar 22;12:e86002. doi: 10.7554/eLife.86002.
4
The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis.治疗性血浆置换与 COVID-19 危重症患者死亡率之间的关联：一项荟萃分析。
F1000Res. 2021 Dec 14;10:1280. doi: 10.12688/f1000research.74972.1. eCollection 2021.
5
Peripheral neurological complications during COVID-19: A single center experience.COVID-19 相关外周神经系统并发症：单中心经验。
J Neurol Sci. 2022 Mar 15;434:120118. doi: 10.1016/j.jns.2021.120118. Epub 2021 Dec 23.
6
TEG, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy.血栓弹力图、微凝块检测和血小板功能检测用于指导重症新型冠状病毒肺炎凝血病的早期管理
J Clin Med. 2021 Nov 18;10(22):5381. doi: 10.3390/jcm10225381.
7
Recognizing Dysfunctional Innate and Adaptive Immune Responses Contributing to Liver Damage in Patients With Cirrhosis.认识到导致肝硬化患者肝损伤的功能失调的先天性和适应性免疫反应。
J Clin Exp Hepatol. 2022 May-Jun;12(3):993-1002. doi: 10.1016/j.jceh.2021.10.001. Epub 2021 Oct 14.
8
Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist.COVID-19 后晚期血液学并发症：血液学家面临的新医学问题。
Am J Hematol. 2022 Jan 1;97(1):119-128. doi: 10.1002/ajh.26384. Epub 2021 Nov 8.
9
COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity: Combinations of bacteria and SARS-CoV-2 synergize to induce autoantibodies targeting cardiolipin, cardiolipin-binding proteins, platelet factor 4, prothrombin, and coagulation factors.COVID-19 凝血功能障碍：人类血液蛋白模拟 SARS-CoV-2 病毒、疫苗蛋白和细菌合并感染诱导自身免疫：细菌和 SARS-CoV-2 的组合协同诱导针对心磷脂、心磷脂结合蛋白、血小板因子 4、凝血酶原和凝血因子的自身抗体。
Bioessays. 2021 Dec;43(12):e2100158. doi: 10.1002/bies.202100158. Epub 2021 Oct 22.
10
Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19.血管性血友病因子：一种与 COVID-19 血栓炎症并发症相关的关键糖蛋白。
Chem Biol Interact. 2021 Oct 1;348:109657. doi: 10.1016/j.cbi.2021.109657. Epub 2021 Sep 10.
本文引用的文献
1
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.意大利北部一系列 COVID-19 病例的肺脏尸检结果：一项两中心描述性研究。
Lancet Infect Dis. 2020 Oct;20(10):1135-1140. doi: 10.1016/S1473-3099(20)30434-5. Epub 2020 Jun 8.
2
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.国际血栓与止血学会（ISTH）关于新冠病毒病（COVID-19）凝血病识别与管理的临时指南。
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
3
Severe COVID-19 infection associated with endothelial activation.严重的2019冠状病毒病感染与内皮细胞激活有关。
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
4
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
5
Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock.治疗性血浆置换对感染性休克内皮激活和凝血相关参数的影响。
Crit Care. 2020 Mar 2;24(1):71. doi: 10.1186/s13054-020-2799-5.
6
Rodenticidal hepatotoxicity: Raised plasma Von Willebrand factor levels predict in-hospital survival and preliminary report of the outcome of Von Willebrand factor reducing management protocol.杀鼠剂肝毒性：血浆血管性血友病因子水平升高可预测住院生存率及血管性血友病因子降低治疗方案结果的初步报告。
Indian J Gastroenterol. 2019 Dec;38(6):527-533. doi: 10.1007/s12664-019-00989-w. Epub 2020 Feb 19.
7
Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.血浆血管性血友病因子水平可预测慢性肝衰竭急性发作患者的院内生存率。
Indian J Gastroenterol. 2016 Nov;35(6):432-440. doi: 10.1007/s12664-016-0708-2. Epub 2016 Nov 8.
Zotero 插件